Sandoz has opened a high-tech biosimilar production centre in Lendava, Slovenia. The facility uses smart automation and process analytical technology.
Sandoz has opened a high-tech biosimilar production centre in Lendava, Slovenia, marking an important step toward achieving its Bio100 ambition of building a portfolio of more than 100 biosimilars by 2040. The facility uses smart automation and process analytical technology, with quality-by-design principles embedded throughout the process, from development to large-scale manufacturing. Employing more than 300 specialists, the site meets international safety, quality and environmental standards. It is the company’s second major biosimilar investment in Slovenia this year, following the opening of a development centre in Ljubljana.